Zheng Quan Shi Bao Wang·2025-10-30 13:54Core Insights - Shanghai Pharmaceuticals reported a revenue of 215.07 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 2.6% [1] - The company achieved a net profit attributable to shareholders of 5.15 billion yuan, marking a significant increase of 26.96% year-on-year [1] Financial Performance - Total revenue for the first three quarters: 215.07 billion yuan [1] - Pharmaceutical manufacturing sales: 18.16 billion yuan [1] - Pharmaceutical commercial sales: 196.91 billion yuan [1] - Net profit attributable to shareholders: 5.15 billion yuan [1] - Year-on-year net profit growth: 26.96% [1] Research and Development - R&D investment for the first three quarters: 1.73 billion yuan [1] - Total new drug pipeline: 57 items, including 45 innovative drugs [1] - NDA submission for BCD-085, an innovative monoclonal antibody for ankylosing spondylitis [1] - Completion of subject enrollment for the Phase III clinical trial of a traditional Chinese medicine for cervical spondylotic myelopathy [1] - Ongoing Phase I clinical trial for CAR-T injection B019 targeting pediatric acute lymphoblastic leukemia and adult lymphoma [1] Brand and Market Strategy - Shanghai Pharmaceuticals is focusing on brand rejuvenation to meet young consumer demands [2] - Launch of the "Ten Complete Series" food paste under the Lei's brand and the "Zero Snack Nourishment" concept under the Shenxiang brand [2] - Successful export of traditional Chinese medicine products to Canada, including the first self-certified compound preparation [2] - Strategic partnerships with companies like Baxter China and others to provide comprehensive health solutions [2]